Current Controversies in Prenatal Diagnosis—Conference Debate 2024: All Fetuses Undergoing Fetal Therapy Should Have Exome Sequencing
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6784 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Prenatal Diagnosis, 2025. Verfasst von Teresa N Sparks und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine and Reproductive Genetics, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of Californi…. Hauptthemen laut MEDLINE: Exome Sequencing, Prenatal Diagnosis, Fetal Therapies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This manuscript summarises the debate held at the 2024 annual meeting of The International Society for Prenatal Diagnosis (ISPD). Experts discussed whether all fetuses undergoing fetal therapy should undergo exome sequencing. Arguments in favor included that, with increasing experience and better clinical availability, exome sequencing can yield valuable diagnostic and prognostic information beyond what is available from karyotyping and microarray. This additional information is often helpful in counseling parents and provides a better understanding of fetal conditions, allowing for personalised medicine and supporting advancements in disease‐focused fetal therapies. On the contrary, however, significant concerns regarding availability and health equity were raised. Moreover, potential delays in care incurred by exome sequencing may negatively affect outcomes of fetal intervention. Finally, as the information gathered from genetic testing may or may not affect pregnancy management decisions beyond termination of pregnancy, many families may choose not to undertake testing. The arguments of both debaters document current controversies in exome sequencing and genetic testing in general. This was also reflected in a divided audience vote at the end of the debate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Maternal-Fetal Medicine and Reproductive Genetics, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, California, USA.
- Prenatal Diagnosis and Fetal Surgery Center, Fetal Medicine Mexico Institute, Guadalajara, Mexico.
- Department of Obstetrics and Gynaecology, Ontario Fetal Centre and Fetal Medicine Unit, Mount Sinai Hospital and University of Toronto, Toronto, Canada.
ORCID-Profile: Teresa N Sparks, Tim Van Mieghem
Zitieren
APA
Sparks, T. N., Cruz Martinez, R., & Van Mieghem, T. (2025). Current Controversies in Prenatal Diagnosis—Conference Debate 2024: All Fetuses Undergoing Fetal Therapy Should Have Exome Sequencing. Prenatal Diagnosis. https://doi.org/10.1002/pd.6784
Vancouver
Sparks TN, Cruz Martinez R, Van Mieghem T. Current Controversies in Prenatal Diagnosis—Conference Debate 2024: All Fetuses Undergoing Fetal Therapy Should Have Exome Sequencing. Prenatal Diagnosis. 2025. doi:10.1002/pd.6784
BibTeX
@article{Sparks2025,
author = {Sparks, Teresa N and Cruz Martinez, Rogelio and Van Mieghem, Tim},
title = {Current Controversies in Prenatal Diagnosis—Conference Debate 2024: All Fetuses Undergoing Fetal Therapy Should Have Exome Sequencing},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6784}
}
EUVIMED